Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Ellard

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|June 24, 2008
The paper trail to mental healthJohn Ellard
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|February 18, 2005
The future revealed?John Ellard
The Australian and New Zealand Journal of Psychiatry|January 21, 2004
Philosophical dimensions for psychiatryJohn Ellard
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|September 11, 2007
Euthanasia: the final paradoxJohn Ellard
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|February 18, 2005
Movement disorders and the treatment of schizophreniaJohn Ellard
Journal of Combinatorial Chemistry|January 16, 2002
Protecting groups in solid-phase organic synthesisDavid Orain, John Ellard, Mark Bradley
Chemical Communications (Cambridge, England)|October 2, 2003
Cell penetrable peptoid carrier vehicles: synthesis and evaluationIlaria Peretto, Rosario M Sanchez-Martin, Xui-hong Wang, et al.
British Journal of Pharmacology|December 6, 2002
L-arginyl-3,4-spermidine is neuroprotective in several in vitro models of neurodegeneration and in vivo ischaemia without suppressing synaptic transmissionBarclay Morrison, Ashley K Pringle, Terence McManus, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinasesThomas P Matthews, Tatiana McHardy, Suki Klair, et al.
Journal of Medicinal Chemistry|November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphingJohn C Reader, Thomas P Matthews, Suki Klair, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|June 24, 2008
The paper trail to mental healthJohn Ellard
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|February 18, 2005
The future revealed?John Ellard
The Australian and New Zealand Journal of Psychiatry|January 21, 2004
Philosophical dimensions for psychiatryJohn Ellard
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|September 11, 2007
Euthanasia: the final paradoxJohn Ellard
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|February 18, 2005
Movement disorders and the treatment of schizophreniaJohn Ellard
Journal of Combinatorial Chemistry|January 16, 2002
Protecting groups in solid-phase organic synthesisDavid Orain, John Ellard, Mark Bradley
Chemical Communications (Cambridge, England)|October 2, 2003
Cell penetrable peptoid carrier vehicles: synthesis and evaluationIlaria Peretto, Rosario M Sanchez-Martin, Xui-hong Wang, et al.
British Journal of Pharmacology|December 6, 2002
L-arginyl-3,4-spermidine is neuroprotective in several in vitro models of neurodegeneration and in vivo ischaemia without suppressing synaptic transmissionBarclay Morrison, Ashley K Pringle, Terence McManus, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinasesThomas P Matthews, Tatiana McHardy, Suki Klair, et al.
Journal of Medicinal Chemistry|November 25, 2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphingJohn C Reader, Thomas P Matthews, Suki Klair, et al.
Pageof 1